A TECHNOLOGY BET
A TECHNOLOGY BET
复制标题
技术赌注
DOI：
10.1021/cen-v086n029.p030
复制
发表时间：
2008
期刊：
影响因子：
--
通讯作者：
L. Jarvis
中科院分区：
文献类型：
--
作者：
L. Jarvis
帝斯曼的医药产品业务在为制药和生物技术行业服务的几十年中经历了许多唐斯。现在，它处于一个药物批准长期处于低位的环境中，定制制造业的竞争非常坚韧，降低医疗保健成本的压力也很大。该公司依靠其技术基础生存，甚至蓬勃发展。去年秋天，帝斯曼重新审视了2005年制定的五年增长战略，并发誓要加快向生命和材料科学公司的转型。该战略的一个主要组成部分是在其服务的市场上利用其生物技术平台。例如，帝斯曼在酶转化方面的专业知识可用于生产生物燃料、合成复杂的活性药物成分（API）或开发功能性食品成分。当然，该生物技术平台的受益者之一是该公司的医药产品业务。去年的销售额约为7.8亿美元，...
DSM’S PHARMACEUTICAL products business has weathered many ups and downs in its decades of serving the pharmaceutical and biotech industries. Now it’s in an environment where drug approvals are at a longtime low, competition in the custom manufacturing industry is tough, and the pressure to lower the cost of health care is acute. The business is banking on its technology base to survive, and even thrive. Last fall, DSM revisited the five-year growth strategy it laid out in 2005 and vowed to accelerate its transition into a life and materials sciences company. A major component of that strategy is to exploit its biotechnology platform across the markets it serves. For example, DSM’s expertise in enzymatic conversions can be used to generate biofuels, synthesize complex active pharmaceutical ingredients (APIs), or develop functional food ingredients. One beneficiary of that biotechnology platform is, of course, the company’s pharmaceutical products business. With roughly $780 million in sales last year, ...